New Manufacturing Process Patent for Ox-1

Strengthens long-term commercial value and partnering potential

TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that it has filed a new process patent covering novel aspects of the manufacturing method for its lead programme, a selective orexin-1 receptor antagonist (Ox-1) being developed for addiction.

The patent, when granted, will protect for 20 years from filing, potentially to 2046, extends the commercial exclusivity for the Ox-1 blocker across major markets, substantially beyond the life of the existing global Composition of Matter patent. The filing follows recent successful manufacturing optimisation and scale-up work during which several novel and efficiency-enhancing chemical process improvements were identified.

Process patents provide an additional barrier to generic competition, as alternative manufacturing routes must be developed to avoid infringement, which are typically not undertaken by competitors. The filing builds on the Company's recently announced strengthening of the Ox-1 patent estate across key global markets and forms part of its broader strategy to establish a robust intellectual property portfolio as the programme advances towards completing the data required for clinical readiness later in 2026.

Dr Huw Jones, Chief Executive Officer of TheraCryf, commented:

"This new process patent submission further strengthens the intellectual property protection surrounding our lead asset and has the potential to extend its commercial exclusivity very substantially.

As TheraCryf progresses swiftly towards clinical development, expanding our broad and defensible patent portfolio is central to maximising the long-term commercial value of the programme and its attractiveness to potential partners."